2-Chloro-1,3-bis(dimentylamino)trimethinium hexafluorophosphate

We are 2-Chloro-1,3-bis(dimentylamino)trimethinium hexafluorophosphate CAS:249561-98-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 2-Chloro-1,3-bis(dimentylamino)trimethinium hexafluorophosphate
CAS.NO:  249561-98-6
Synonyms:
2-Chloro-1,3-bis(dimentylamino)trimethinium hexafluorophosphate
N-[(2Z)-2-Chloro-3-(dimethylamino)prop-2-en-1-ylidene]-N-methylmethanaminium hexafluorophosphate
N,N-DiMethyl-2-chloro-triMethiniuM Hexafluorophosphate
(2Z)-2-Chloro-3-(dimethylamino)-N,N-dimethyl-2-propen-1-iminium hexafluorophosphate
2-Chloro-1,3-bis(dimethylamino)trimethinium hexafluorophosphate
2-Chloro-1,3-bis(dimentylamino)trimethiniumhexafluorophosphate

Molecular Formula: C7H14ClF6N2P
Molecular Weight:   306.61700

Physical and Chemical Properties:

Specification:
Appearance: White Powder
Purity:≥99.0%
Water:0.5% Max.
Sulfated ash:0.1% Max.
Total Impurity:0.5% Max.

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Etoricoxib CAS:202409-33-4.

Related News: In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.Sodium L-Ascorbyl-2-Phosphate CAS:66170-10-3 Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.56830-58-1 In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.11α-hidroxi canrenona CAS:192569-17-8 Targets within the tumor microenvironment may include both plasma membrane proteins as well as proteins typically secreted into the extracellular space.ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.